Company Overview and News

3
58 Of 122 Monthly Paid Canadian 'Safer' Dividend Equities For October 2019

2018-10-03 seekingalpha
58 of 122 Monthly Paying (MoPay) Canadian (CAD) equities were "safer" by showing positive annual returns, and free cash flow yield greater than dividend yield.
CRIUF BPZZF CHP.UN RNW THO PPRQF CJR.B DREUF MR.UN EFRTF SBC DR.DB.A TRSWF TAHO ARESF SRRTF DR KWH.UN BTBIF PZRIF MFCSF DIR.UN CJREF SRT.UN PZA

 
Top 10 Monthly Paying Canadian Dividend Stocks With Large 1-Year Projected Gains

2018-10-02 seekingalpha
Monthly paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
MGRUF FFN NAF.UN CRIUF MHIVF ATGFF RNW SOT.UN EFRTF AHOTF DR.DB.A DVVDF TRSWF ARESF DR CNDCF KWH.UN BK MFCSF FNCSF ALA

4
Sanchez Midstream Tagged 'Safer' Dividend Follower Favorite Per Stockbroker September Surveys

2018-09-20 seekingalpha
From 8/15/18-9/17/18, Fredrik Arnold dividend "followers" commented on 40 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
KWH.UN VOD VOD SXCP CRIUF ORC DVDDF CHMI CZZ CJREF CIM GMLP VODPF CJR.B CVX AVGO BRCM INTC SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities And Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities & Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

2
60 Monthly Paying 'Safer' Dividend S-M-L Stocks For September

2018-09-17 seekingalpha - 1
60 of 166 Monthly-Paying (MoPay) Small-Mid-Large (SML) Cap US & Canadian Dividend stocks were tagged "safer" by showing positive annual-returns, and free cash-flow yields beyond their dividend yields 9/13/18.
AGNCB CMLEF APLE AGNCP BTBIF CRIUF FCMGF AGNC BPZZF ORC

3
Monthly Paid Dividends From 166 SML Equities And 64 Funds For September

2018-09-16 seekingalpha
It's your September 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays <$200M are not listed.
CRLFF CRIUF ORC MHIVF GLADO ATGFF AGNC TRSWF KWH.UN PSEC SCQ PBB MGRUF SCA CJ GOOD OXLCO OXLCN SCM GOODM GLAD SOT.UN RNW GOODN ECC ECCZ AHOTF ECCY GOODO GOODP SRRTF ARESF CGIFF PZRIF ?NHF? OXLC ECCB ARR ECCA SUNS GNL NHF ALA SRT.UN PZA

3
52 Monthly Paid Canadian 'Safer' Dividend Equities Of 132 Revealed For September 2019

2018-09-01 seekingalpha
52 of 132 monthly paying Canadian "safer" equities showed positive annual returns and free cash flow yield greater than dividend yield per market data gathered 8/27/18.
TAHO KWH.UN BTBIF CRIUF DVSPF CJREF THO CJR.B MR.UN EFRTF SBC

 
132 Monthly Pay Canadian Dividend Stocks Flaunt 1.73% To 50% Yields To September 2019

2018-08-31 seekingalpha
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
OSP CCAOF CNDCF FFN KWH.UN CBL NAF.UN BK CRIUF MHIVF DVSPF ATGFF EFRTF AHOTF FNCSF

1
54 Monthly Paying 'Safer' Dividend S-M-L Stocks For August

2018-08-24 seekingalpha
54 of 156 Monthly-Paying (MoPay) Small-Mid-Large (SML) Cap US & Canadian Dividend stocks were tagged "safer" by showing positive annual-returns, and free cash-flow yields over dividend yields 8/22/18.
AGNCB CMLEF APLE CRIUF BPZZF ORC CHP.UN DIR.UN CWYUF AGNCP DREUF FCMGF AGNC

4
Monthly Paid Dividends From 156 SML Equities And 66 Funds For August

2018-08-24 seekingalpha
Here's your August 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays are not listed.
MGRUF SCA CJ CRLFF CRIUF ORC MHIVF RA OXLCO OXLCN SCM GLADO ATGFF GLAD SOT.UN RNW ECC ECCZ AGNC AHOTF ECCY TRSWF SRRTF KWH.UN CGIFF ?NHF? PSEC OXLC ECCB ARR SCQ ECCA SUNS GNL NHF PBB ALA OPP SRT.UN

 
Crius Energy Trust 2018 Q2 - Results - Earnings Call Slides

2018-08-13 seekingalpha
The following slide deck was published by Crius Energy Trust in conjunction with their 2018 Q2 earnings call.
KWH.UN CRIUF

4
Get 48 'Safer' Dividends Paid Monthly From 131 Canadian August Equities

2018-08-12 seekingalpha - 1
48 of 131 Monthly Paying (MoPay) Canadian (CAD) Equities were "safer" by their positive annual returns, and free cash flow yield greater than dividend yield per market data gathered 8/7/18. Quotes = $CAD.
TAHO CCAOF CBL CGIFF BTBIF CRIUF CIFAF DVSPF CJREF THO PPRQF CJR.B CIX FCMGF MR.UN

 
131 Monthly Pay Canadian Dividend Stocks Cast 0.45% To 20.41% Yields To August 2019

2018-08-11 seekingalpha
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead of just once, twice, or four times.
OSP CCAOF CNDCF GXOCF CJ FFN NAF.UN BK CRLFF CGIFF CRIUF MHIVF DVSPF LCS ATGFF RNW SOT.UN GXO EFRTF AHOTF FNCSF TRSWF

2
52 'Safer' S-M-L Monthly Paying Dividend Stocks Led By Crius July Gains

2018-07-24 seekingalpha - 1
52 of 148 Monthly-Pay (MoPay) Small-Mid-Large (SML) Cap US and Canadian Dividends were tagged "safer" by showing positive annual-returns, and free-cash-flow yields beyond their dividend yields as of 7/20/18.
AGNCB APLE CGIFF CRIUF CIFAF ORC ARR CJREF CJR.B AGNCP CIX AGNC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 22676R115